Selective estrogen receptor modulators and risk for coronary heart disease

References

• American Heart Association (http://www. americanheart.org)
   Google Scholar
• Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European Cardiovascular Disease Statistics2005 edn. European Heart Network and British Heart Foundation, http://www.ehnheart.org/files/statistics%202005-092711A.pdf
   Google Scholar
• Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55–72
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Cano A, Hermenegildo C. Modulation of the oestrogen receptor: a process with distinct susceptible steps. Hum Reprod Update 2000; 6: 207–211
   PubMed Web of Science ®Google Scholar
• Sanz-Gonzalez S M, Cano A, Valverde M A, Hermenegildo C, Andres V. Drug targeting of estrogen receptor signaling in the cardiovascular system: preclinical and clinical studies. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 107–122
   PubMedGoogle Scholar
• Ouyang P, Michos E D, Karas R H. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol 2006; 47: 1741–1753
   PubMed Web of Science ®Google Scholar
• Cano A. Estrogen receptor modulation. Updates in Infertility Treatment, M Filicori. Medimond, BolognaItaly 2004; 265–280
   Google Scholar
• Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258–4265
   PubMed Web of Science ®Google Scholar
• Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002; 295: 505–508
   PubMed Web of Science ®Google Scholar
• Weihua Z, Andersson S, Cheng G, Simpson E R, Warner M, Gustafsson J A. Update on estrogen signaling. FEBS Lett 2003; 546: 17–24
   PubMed Web of Science ®Google Scholar
• Harrington W R, Sheng S, Barnett D H, Petz L N, Katzenellenbogen J A, Katzenellenbogen B S. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 2003; 206: 13–22
   PubMed Web of Science ®Google Scholar
• Muthyala R S, Sheng S, Carlson K E, Katzenellenbogen B S, Katzenellenbogen J A. Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor. J Med Chem 2003; 46: 1589–1602
   PubMed Web of Science ®Google Scholar
• Ghosh U, Ganessunker D, Sattigeri V J, et al. Estrogenic diazenes: heterocyclic non-steroidal estrogens of unusual structure with selectivity for estrogen receptor subtypes. Bioorg Med Chem 2003; 11: 629–657
   PubMed Web of Science ®Google Scholar
• Shibata H, Spencer T E, Oñate S A, et al. Role of co-activators and co-repressors in the mechanism of steroid-thyroid receptor action. Rec Prog Horm Res 1997; 52: 141–165
   PubMedGoogle Scholar
• Hall J M, Couse J F, Korach K S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276: 36869–36872
   PubMed Web of Science ®Google Scholar
• Kousteni S, Han L, Chen J R, et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 2003; 111: 1651–1664
   PubMed Web of Science ®Google Scholar
• Li L, Haynes M P, Bender J R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 2003; 100: 4807–4812
   PubMed Web of Science ®Google Scholar
• Mendelsohn M E. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Mol Biol 2000; 74: 337–343
   PubMed Web of Science ®Google Scholar
• Mendelsohn M E. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002; 90(1A)3–6F
   Google Scholar
• Marin F, Barbancho M C. Clinical Pharmacology of selective estrogen receptor modulators (SERMs). Selective Estrogen Receptor Modulators. New Brand of Multitarget Drugs, A Cano, J Calaf i Alsina, J L Duenas-Diez. Springer, BerlinGermany 2006; 49–69
   Google Scholar
• Vogel V G, Costantino J P, Wickerham D L, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727–2741
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–137
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani A R, Liao J K. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002; 105: 1368–1373
   PubMed Web of Science ®Google Scholar
• Simoncini T, Varone G, Fornari L, et al. Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology 2002; 143: 2052–2061
   PubMed Web of Science ®Google Scholar
• Oviedo P J, Hermenegildo C, Cano A. Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2. Menopause 2004; 11: 430–437
   PubMed Web of Science ®Google Scholar
• Oviedo P, Hermenegildo C, Tarín J J, Cano A. Raloxifene promotes prostacyclin release in human endothelial cells role of COX-1 and COX-2. Fertil Steril 2005; 83: 1822–1829
   PubMed Web of Science ®Google Scholar
• Patterson A J, Henrie-Olson J, Brenner R. Vasoregulation at the molecular level: a role for the beta1 subunit of the calcium-activated potassium (BK) channel. Trends Cardiovasc Med 2002; 12: 78–82
   PubMed Web of Science ®Google Scholar
• Díaz M. Triphenylethylene antiestrogen-induced acute relaxation of mouse duodenal muscle. Possible involvement of calcium channels. Eur J Pharmacol 2002; 445: 257–266
   PubMed Web of Science ®Google Scholar
• Tsang S Y, Yao X, Essin K, et al. Raloxifene relaxes rat cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca2+ channels. Stroke 2004; 35: 1709–1714
   PubMed Web of Science ®Google Scholar
• Mercier I, Mader S, Calderone A. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc Res 2003; 59: 883–892
   PubMed Web of Science ®Google Scholar
• Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295: 2465–2468
   PubMed Web of Science ®Google Scholar
• Engelke M, Tykhonova S, Zorn-Kruppa M, Diehl H. Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 2002; 91: 13–21
   PubMedGoogle Scholar
• Wiseman H, Quinn P, Halliwell B. Tamoxifen and related compounds decrease membrane fluidity in liposomes. Mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions?. FEBS Lett 1993; 330: 53–56
   PubMed Web of Science ®Google Scholar
• Resch U, Mellauner V, Budinsky A, Sinzinger H. Inhibition of low-density lipoprotein and high-density lipoprotein oxidation by raloxifene. J Womens Health (Larchmt) 2004; 13: 404–411
   PubMed Web of Science ®Google Scholar
• Zuckerman S H, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis 1996; 126: 65–75
   PubMed Web of Science ®Google Scholar
• Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause 2003; 10: 142–146
   PubMed Web of Science ®Google Scholar
• Hermenegildo C, Garcia-Martinez M C, Tarin J J, Cano A. Inhibition of low-density lipoprotein oxidation by the pure antiestrogens ICI 182780 and EM-652 (SCH 57068). Menopause 2002; 9: 430–435
   PubMed Web of Science ®Google Scholar
• Baumer A T, Wassmann S, Ahlbory K, et al. Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene. Br J Pharmacol 2001; 134: 579–584
   PubMed Web of Science ®Google Scholar
• Rahimian R, Dube G P, Toma W, Dos Santos N, McManus B M, van Breemen C. Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur J Pharmacol 2002; 434: 141–149
   PubMed Web of Science ®Google Scholar
• Christopher T A, Lopez B L, Stillwagon J C, et al. Idoxifene causes endothelium-dependent, nitric oxide-mediated vasorelaxation in male rats. Eur J Pharmacol 2002; 446: 139–143
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez J, Crespo M J. Chronic effects of toremifene on the vasculature of menopause-induced rats. Vascul Pharmacol 2003; 40: 261–268
   PubMed Web of Science ®Google Scholar
• Thorin E, Pham-Dang M, Clement R, Mercier I, Calderone A. Hyper-reactivity of cerebral arteries from ovariectomized rats: therapeutic benefit of tamoxifen. Br J Pharmacol 2003; 140: 1187–1192
   PubMed Web of Science ®Google Scholar
• Tatchum-Talom R, Martel C, Labrie F, Marette A. Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. Cardiovasc Res 2003; 57: 535–543
   PubMed Web of Science ®Google Scholar
• Figtree G A, Webb C M, Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide- and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther 2000; 295: 519–523
   PubMed Web of Science ®Google Scholar
• Hutchison S J, Chou T M, Chatterjee K, Sudhir K. Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. J Cardiovasc Pharmacol 2001; 38: 657–665
   PubMed Web of Science ®Google Scholar
• Gaynor J S, Monnet E, Selzman C, Parker D, Kaufman L, Bryant H U, et al. The effect of raloxifene on coronary arteries in aged ovariectomized ewes. J Vet Pharmacol Ther 2000; 23: 175–179
   PubMed Web of Science ®Google Scholar
• Wassmann S, Laufs U, Stamenkovic D, et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002; 105: 2083–2091
   PubMed Web of Science ®Google Scholar
• Somjen D, Kohen F, Jaffe A, Amir-Zaltsman Y, Knoll E, Stern N. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 1998; 32: 39–45
   PubMed Web of Science ®Google Scholar
• Takahashi K, Ohmichi M, Yoshida M, et al. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol 2003; 178: 319–329
   PubMed Web of Science ®Google Scholar
• Mori-Abe A, Tsutsumi S, Takahashi K, et al. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J Endocrinol 2003; 178: 417–426
   PubMed Web of Science ®Google Scholar
• Dubey R K, Tyurina Y Y, Tyurin V A, et al. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res 1999; 84: 229–239
   PubMed Web of Science ®Google Scholar
• Reckless J, Metcalfe J C, Grainger D J. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 1997; 95: 1542–1548
   PubMed Web of Science ®Google Scholar
• Selzman C H, Turner A S, Gaynor J S, Miller S A, Monnet E, Harken A H. Inhibition of intimal hyperplasia using the selective estrogen receptor modulator raloxifene. Arch Surg 2002; 137: 333–336
   PubMed Web of Science ®Google Scholar
• Bjarnason N H, Haarbo J, Byrjalsen I, Kauffman R F, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997; 96: 1964–1969
   PubMed Web of Science ®Google Scholar
• Bjarnason N H, Haarbo J, Byrjalsen I, Kauffman R F, Knadler M P, Christiansen C. Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin Endocrinol (Oxf) 2000; 52: 225–233
   PubMed Web of Science ®Google Scholar
• Bjarnason N H, Haarbo J, Byrjalsen I, Alexandersen P, Kauffman R F, Christiansen C. Raloxifene and estrogen reduces progression of advanced atherosclerosis – a study in ovariectomized, cholesterol-fed rabbits. Atherosclerosis 2001; 154: 97–102
   PubMed Web of Science ®Google Scholar
• Clarkson T B, Anthony M S, Jerome C P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998; 83: 721–726
   PubMed Web of Science ®Google Scholar
• Yue T L, Vickery-Clark L, Louden C S, et al. Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization, and inhibits neointimal formation in vivo after vascular injury. Circulation 2000; 102(Suppl 3)281–288
   Google Scholar
• Saarto T, Blomqvist C, Ehnholm C, Taskinen M R, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996; 14: 429–433
   PubMed Web of Science ®Google Scholar
• Delmas P D, Bjarnason N H, Mitlak B H, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–1647
   PubMed Web of Science ®Google Scholar
• Walsh B W, Kuller L H, Wild R A, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445–1451
   PubMed Web of Science ®Google Scholar
• Joensuu H, Holli K, Oksanen H, Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000; 63: 225–234
   PubMed Web of Science ®Google Scholar
• Herrington D M, Pusser B E, Riley W A, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2000; 20: 1606–1612
   PubMed Web of Science ®Google Scholar
• Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003; 95: 779–790
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208
   PubMed Web of Science ®Google Scholar
• Mosca L, Barrett-Connor E, Wenger N K, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001; 88: 392–395
   PubMed Web of Science ®Google Scholar
• Reid I R, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004; 164: 871–879
   PubMed Web of Science ®Google Scholar
• Hozumi Y, Kawano M, Miyata M. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J 1997; 44: 745–749
   PubMed Web of Science ®Google Scholar
• Kanel K T, Wolmark N, Thompson P D. Delayed severe hypertriglyceridemia from tamoxifen. N Engl J Med 1997; 337: 281
   PubMed Web of Science ®Google Scholar
• Anderson P W, Cox D A, Sashegyi A, Paul S, Silfen S L, Walsh B W. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 2001; 39: 71–77
   PubMed Web of Science ®Google Scholar
• Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause 2003; 10: 440–447
   PubMed Web of Science ®Google Scholar
• Vogelvang T E, Mijatovic V, Kenemans P, Teerlink T, van der Mooren M J. HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertil Steril 2004; 82: 1540–1549
   PubMed Web of Science ®Google Scholar
• Oviedo P, Hermenegildo C, Tarín J J, Cano A. Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2α-isoprostane levels in postmenopausal women. Fertil Steril 2005; 84: 1789–1792
   PubMed Web of Science ®Google Scholar
• Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512–1519
   PubMed Web of Science ®Google Scholar
• Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003; 88: 2135–2140
   PubMed Web of Science ®Google Scholar
• Sarrel P M, Nawaz H, Chan W, Fuchs M, Katz D L. Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 2003; 188: 304–309
   PubMed Web of Science ®Google Scholar
• Ceresini G, Marchini L, Rebecchi I, et al. Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women. Atherosclerosis 2003; 167: 121–127
   PubMed Web of Science ®Google Scholar
• Griffiths K A, Sader M A, Skilton M R, Harmer J A, Celermajer D S. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003; 42: 698–704
   PubMed Web of Science ®Google Scholar
• Koh K K, Bui M N, Mincemoyer R, Cannon R O, 3rd. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997; 80: 1505–1507
   PubMed Web of Science ®Google Scholar
• Blum A, Schenke W H, Hathaway L, et al. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am J Cardiol 2000; 86: 892–895
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Flevari P, Kroupis C, Kyriakides Z S, Koniavitou K, Kremastinos D T. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther 2003; 17: 319–323
   PubMed Web of Science ®Google Scholar
• Simoncini T, De Caterina R, Genazzani A R. Selective estrogen receptor modulators: different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Clin Endocrinol Metab 1999; 84: 815–818
   PubMed Web of Science ®Google Scholar
• Herrington D M, Brosnihan K B, Pusser B E, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001; 86: 4216–4222
   PubMed Web of Science ®Google Scholar
• Simon T, Boutouyrie P, Simon J M, et al. Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. Circulation 2002; 106: 2925–2929
   PubMed Web of Science ®Google Scholar
• Stamatelopoulos K S, Lekakis J P, Poulakaki N A, et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 2004; 147: 1093–1099
   PubMed Web of Science ®Google Scholar
• Orbe J, Fernandez L, Rodriguez J A, et al. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 2003; 170: 269–276
   PubMed Web of Science ®Google Scholar
• Kong Y Z, Yu X, Tang J J, et al. Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis 2005; 178: 207–215
   PubMed Web of Science ®Google Scholar
• Kong Y Z, Huang X R, Ouyang X, et al. Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc Res 2005; 65: 272–282
   PubMed Web of Science ®Google Scholar
• Zanger D, Yang B K, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000; 36: 1797–1802
   PubMed Web of Science ®Google Scholar
• Ardans J A, Blum A, Mangan P R, Wientroub S, Cannon R O, 3rd, Wahl L M. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. Arterioscler Thromb Vasc Biol 2001; 21: 1265–1268
   PubMed Web of Science ®Google Scholar
• Davison S, Davis S R. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003; 88: 2470–2478
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer E G, McGeer P L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039–1051
   PubMed Web of Science ®Google Scholar
• Charo I F, Taubman M B. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858–866
   PubMed Web of Science ®Google Scholar
• Boyle J J. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005; 3: 63–68
   PubMedGoogle Scholar
• Elhage R, Clamens S, Besnard S, et al. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 2001; 156: 315–320
   PubMed Web of Science ®Google Scholar
• Seli E, Pehlivan T, Selam B, Garcia-Velasco J A, Arici A. Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells. Fertil Steril 2002; 77: 542–547
   PubMed Web of Science ®Google Scholar
• Walsh B W, Paul S, Wild R A, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85: 214–218
   PubMed Web of Science ®Google Scholar
• Cushman M, Costantino J P, Tracy R P, et al. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001; 21: 255–261
   PubMed Web of Science ®Google Scholar
• Walsh B W, Cox D A, Sashegyi A, Dean R A, Tracy R P, Anderson P W. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001; 88: 825–828
   PubMed Web of Science ®Google Scholar
• Gianni W, Ricci A, Gazzaniga P, et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 2004; 89: 6097–6099
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Netelenbos C, van der Mooren M J, de Valk-de Roo G W, Jakobs C, Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 1998; 70: 1085–1089
   PubMed Web of Science ®Google Scholar
• De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 2001; 184: 350–353
   PubMed Web of Science ®Google Scholar
• Smolders R G, Vogelvang T E, Mijatovic V, et al. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 2002; 41: 105–114
   PubMed Web of Science ®Google Scholar
• Miller A P, Chen Y F, Xing D, Feng W, Oparil S. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 2003; 42: 657–663
   PubMedGoogle Scholar
• Badimon J J, Zaman A, Helft G, Fayad Z, Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost 1999; 82: 997–1004
   PubMed Web of Science ®Google Scholar
• Bar J, Tepper R, Fuchs J, Pardo J, Goldberger S, Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 1993; 81: 261–264
   PubMed Web of Science ®Google Scholar
• Nakano Y, Oshima T, Matsuura H, Kajiyama G, Kambe M. Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis. Arterioscler Thromb Vasc Biol 1998; 18: 961–967
   PubMed Web of Science ®Google Scholar
• Chen F PL, Lee N, Wang C H, Soong Y K. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998; 69: 267–273
   PubMed Web of Science ®Google Scholar
• Bar J, Lahav J, Hod M, Ben-Rafael Z, Weinberger I, Brosens J. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17beta-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost 2000; 84: 695–700
   PubMed Web of Science ®Google Scholar
• García-Martínez M C, Labiós M, Hermenegildo C, Tarín J J, O'Connor E, Cano A. The effect of hormone replacement therapy on Ca2+ mobilization and P-selectin (CD62P) expression in platelets examined under flow cytometry. Blood Coagul Fibrinolysis 2004; 15: 1–8
   PubMed Web of Science ®Google Scholar
• Boudoulas K D, Montague C R, Goldschmidt-Clermont P J, Cooke G E. Estradiol increases platelet aggregation in Pl(A1/A1) individuals. Am Heart J 2006; 152: 136–139
   PubMed Web of Science ®Google Scholar
• Jayachandran M, Mukherjee R, Steinkamp T, et al. Differential effects of 17{beta}-estradiol, conjugated equine estrogen and raloxifene on mRNA expression, aggregation and secretion in platelets. Am J Physiol Heart Circ Physiol 2005; 288: H2355–H2362
   PubMed Web of Science ®Google Scholar
• Miller M E, Dores G M, Thorpe S L, Akerley W L. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res 1994; 74: 577–594
   PubMed Web of Science ®Google Scholar
• Miller M E, Thorpe S L, Dores G M. Influence of hormones on platelet intracellular calcium. Thromb Res 1995; 77: 515–530
   PubMed Web of Science ®Google Scholar
• de Valk-de Roo G W, Stehouwer C D, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999; 19: 2993–3000
   PubMed Web of Science ®Google Scholar
• Reis S E, Costantino J P, Wickerham D L, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001; 93: 16–21
   PubMed Web of Science ®Google Scholar
• Harman S M, Brinton E A, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 1–2
   Google Scholar
• Delmas P D, Ensrud K E, Adachi J D, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609–3617
   PubMed Web of Science ®Google Scholar